Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Lannett Co's Capital Expenditure for the
three
months ended in Mar. 2023 was $-1.40 Mil. Its Revenue for the
three
months ended in Mar. 2023 was $80.51 Mil.
Hence, Lannett Co's Capex-to-Revenue for the
three
months ended in Mar. 2023 was 0.02.
Lannett Co Capex-to-Revenue Historical Data
The historical data trend for Lannett Co's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lannett Co's Capex-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Lannett Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lannett Co's Capex-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lannett Co's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Lannett Co's Capex-to-Revenue falls into.
Lannett Co Capex-to-Revenue Calculation
Lannett Co's Capex-to-Revenue for the fiscal year that ended in Jun. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lannett Co (OTCPK:LCINQ) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Lannett Co Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Lannett Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LCINQ has been successfully added to your 